CAMBRIDGE, Mass.--Variagenics announced the appointment of Colin Dykes to the newly created position of vice-president, genomics. Dykes had a 16-year career at Glaxo Wellcome before joining Variagenics, a firm here that identifies clinically important variances in genes that affect drug action. Dykes established Glaxo's first genetics and genomics programs and most recently served as director of its UK Genetics Division. At Variagenics, Dykes will lead research and development in genomics and pharmacogenomics.